Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival. Methods and results: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64). Conclusion: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Cited by
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
“On the other hand, reduced expression has been shown in particular tumors, such as ovarian [263,264], bladder, and renal cancers [265].”
BackgroundMitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells
Rasola, A., Neckers, L., & Picard, D. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.005 · Cited by 129
Mungenast, F., Aust, S., Vergote, I., Vanderstichele, A., Sehouli, J., Braicu, E., Mahner, S., Castillo-Tong, D. C., Zeillinger, R., & Thalhammer, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.5969 · Cited by 33
Self-citation
Metadata
- Authors
- Aust, S., Bachmayr-Heyda, A., Pateisky, P., Tong, D., Darb-Esfahani, S., Denkert, C., Chekerov, R., Sehouli, J., Mahner, S., Van Gorp, T., Vergote, I., Speiser, P., Horvat, R., Zeillinger, R., & Pils, D.
- Venue
- Molecular Cancer
- Published
- 2012-09-14
- Volume
- 11
- Issue
- 1
- Pages
- 69-69
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2110400064
- Cited by
- 42
- References
- 1
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium. https://app.cochat.ai/papers/10.1186/1476-4598-11-69
- The paper
- Aust, S., Bachmayr-Heyda, A., Pateisky, P., Tong, D., Darb-Esfahani, S., Denkert, C., Chekerov, R., Sehouli, J., Mahner, S., Van Gorp, T., Vergote, I., Speiser, P., Horvat, R., Zeillinger, R., & Pils, D. (2012). Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium. Molecular Cancer. https://doi.org/10.1186/1476-4598-11-69
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.